Lixte Biotechnology Holdings, Inc.

NASDAQ:LIXT

Biotechnology

Healthcare
$7.21 +6.61%

+$0.46 today

Market cap
$89.11M
Beta
1.05
P/E (TTM)
-11.1
EPS (TTM)
-$0.67
52W Low $0.68High $7.78

Volume 0.61M

Average 0.12M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$3.07M

FY 2025 · Annual

Investing Cash Flow

-$3.17M

FY 2025 · Annual

Financing Cash Flow

$10.31M

FY 2025 · Annual

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(6.73M)(6.31M)(5.09M)(3.59M)(6.01M)
Depreciation & Amortization00000
Deferred Income Tax00000
Stock-Based Compensation2.6M1.55M0418.42K1.56M
Change in Working Capital(13.44K)154.76K20.56K3.01K412.88K
Accounts Receivables00000
Inventory00000
Accounts Payables35.67K2.32K(73.98K)(73.55K)0
Other Working Capital(49.11K)152.44K94.54K76.56K412.88K
Other Non-Cash Items00773.2K0966.09K
Operating Cash Flow(4.14M)(4.61M)(4.29M)(3.16M)(3.07M)
Capital Expenditures0(3)0(4)0
Acquisitions (Net)00000
Purchases of Investments0000(3.08M)
Sales of Investments00000
Other Investing Activities0000(95.1K)
Investing Cash Flow0000(3.17M)
Debt Repayment00000
Common Stock Issued3.69M5.14M3.14M010.31M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities207.63K06.32K00
Financing Cash Flow3.9M5.14M3.14M010.31M
Effect of Forex Changes00000
Net Change in Cash(245.52K)529.65K(1.15M)(3.16M)4.07M
Free Cash Flow(4.14M)(4.61M)(4.29M)(3.16M)(3.07M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$6.0M
+ D&A$0
+ Stock-Based Comp$1.6M
+ Deferred Tax$0
+ Working Capital$412.9K
+ Other Non-Cash$966.1K
= Operating Cash Flow-$3.1M
- Capex$0
= Free Cash Flow-$3.1M

Analysis

FY2025 free cash flow is -$3.1M. FCF conversion is 51.1% of net income. Operating cash flow was -$3.1M, with capex of $0. The largest bridge item is Stock-Based Comp at $1.6M.

Competitors

Peer companies in the same sector

Health

Recent Filings

Recent regulatory filings

FilingDescriptionDate
3Initial statement of beneficial ownershipJul 2, 2026
4Statement of changes in beneficial ownershipJul 2, 2026
4Statement of changes in beneficial ownershipJul 2, 2026
4Statement of changes in beneficial ownershipJul 2, 2026
4Statement of changes in beneficial ownershipJul 2, 2026

Does LIXT generate free cash flow?

Lixte Biotechnology Holdings, Inc. (LIXT) generated -$3.07M of free cash flow in fiscal 2025.

How much operating cash flow does LIXT produce?

Operating cash flow was -$3.07M, before capital expenditures of $0.00.